Management of Very High-Risk Prostate Cancer

Introduction to Management

The National Comprehensive Cancer Network (NCCN) recommends long-term neoadjuvant/concomitant/adjuvant androgen deprivation therapy (ADT) for 2-3 years for very high-risk disease (T3b-T4) and high-risk disease (T3a, Gleason 8-10, or PSA >20 ng/mL) treated with definitive radiation 1, 3, 4
The NCCN guidelines specifically recommend long-term ADT (2-3 years) for very high-risk disease (T3b-T4) and high-risk disease (T3a, Gleason 8-10, or PSA >20 ng/mL) treated with definitive radiation 1, 3, 4
RTOG 92-02 demonstrated superior outcomes with long-term (2+ years) versus short-term (4 months) ADT in high-risk patients, with particular benefit in Gleason 8-10 disease showing improved overall survival (45% vs 32%, P=0.0061) 4
EORTC 22961 confirmed superior survival when 2.5 years of ADT was added to RT in patients with T2c-T3 disease 4

Calculate the total ADT duration from initiation to determine when to discontinue, targeting 24-36 months total 1, 2, 5
The American College of Radiology and the National Comprehensive Cancer Network recommend measuring PSA every 3-6 months for the first 5 years, then annually thereafter 1, 6
More frequent PSA testing (every 3 months) may be warranted given the patient's very high-risk classification 1
PSA velocity and doubling time should be calculated at each visit to assess for biochemical recurrence 1, 7

Perform digital rectal examination (DRE) every 6-12 months to assess for local recurrence, as local recurrence can occur even with undetectable PSA in rare cases 1
Consider baseline PSMA PET/CT if not already performed, particularly if PSA becomes detectable or rises, as PSMA PET has superior sensitivity for detecting recurrence compared to conventional imaging 8, 5
Multiparametric MRI combined with PSMA PET provides optimal detection of local intraprostatic recurrence 8

Assess for metabolic, cardiovascular, and bone health complications at each visit, as ADT side effects are cumulative over time and include hot flashes, weight gain, loss of libido, erectile dysfunction, osteoporosis, metabolic syndrome, and cardiovascular risk 2, 7, 9
Consider bone density screening and calcium/vitamin D supplementation 9
Monitor lipid profile, glucose, and cardiovascular risk factors 9
Screen for depression, anxiety, and body image concerns, which are common with ADT 9

If PSA rises (biochemical failure defined as nadir + 2 ng/mL), initiate workup with PSMA PET/CT and multiparametric MRI 8, 5
For local-only intraprostatic recurrence confirmed by imaging and biopsy, salvage options include SBRT, HDR brachytherapy, or LDR brachytherapy with favorable toxicity profiles 8
Systematic and targeted biopsies are both necessary, as each detects approximately 6-8% of cancers missed by the other modality 8
For metastatic recurrence, continue or intensify systemic therapy rather than local salvage 5